

Presentation of proposed board members

The Nomination Committee's proposal AGM 2015 (item 11 in the proposed agenda)



Re-election of

Gregory Batcheller (1957)

Juris Doctor

Chairman since 2008.

Board member since 2000. Extensive experience of working in pharmaceuticals, biotech and medtech.

Chairman of A1M Pharma AB, Monocl AB and Xintela AB.

Partner of Partners för utvecklingsinvesteringar i Life Science, P.U.L.S. AB.

No. of shares: 380,332 privately owned (including family) and 1.74% of Maas Biolab, LLC which owns 13.94% of NeuroVive.

Affiliated to the company and management.



Re-election of

Arne Ferstad (1950)

Economist

Board member since 2010. Broad-based experience of the biotech sector in companies such as Baxter and Pharmacia. Board member of Combigen AB, Medfield Diagnostics AB (publ), Aggancio Research AB, Clinical Laserthermia System AB (publ) and CEO/partner of Ankor Consultants Ltd.

No. of shares: 17,623 privately owned (including family).

Affiliated to the company and management.



Re-election of

Boel Flodgren (1942)

Professor of Commercial Law

Board member since 2013. Experience of research and lecturing in the field of Business Law, including positions at universities such as Stanford and Harvard. Former Principal of Lund University. Board member of AB Industrivärden (publ) and former Board member of Brinova Fastigheter AB, Sparbanken Finn, Lund University, University of Copenhagen and the University of Oslo.

No. of shares: 12,000 privately owned (incl. family)

Non-affiliated to the management, company and major owners.



Re-election of

Marcus Keep (1959)

Associate professor i neurokirurgi vid Penn State Hershey, Pennsylvania, USA

Board member since 2000.

Formerly Associate Professor of neurosurgery at the University of Hawaii and the University of New Mexico. In 1994-1996 Marcus was a guest researcher at Lund University. CEO of Maas Biolab, LLC.

No. of shares: 391,929 privately owned (including family) and 48.41% of Maas Biolab, LLC which owns 13.94% of NeuroVive

Affiliated to the company and management.



Re-election of

Helena Levander (1957)

B.Sc. (Econ)

Board member since 2012. Experience of the stock market and asset management from SEB, Nordea and Odin Fonder. Former CEO of Neonet Securities AB. Board positions include Uniflex Bemanning AB, Stampen AB, Collector AB, Concordia Maritime AB (publ) and Hans Andersson Recycling AB.

No. of shares: 6,250

Non-affiliated to the management, company and major owners.



Re-election of

Anna Malm Bernsten (1961)

M.Sc. Eng.

Board member since 2013. Extensive experience of strategic marketing, product launch and business development in an international setting in pharmaceuticals and biotech companies. Board member of Cellavision AB (publ), Birdstep ASA (publ), Medivir AB (publ) and Chairman of CEBA AB and Oatly AB.

No. of shares: 0

Non-affiliated to the management, company and major owners.



Re-election of

Helmuth von Moltke (1937)

Lawyer

Board member since 2005. Lawyer and venture capitalist, with minor holdings in a number of companies in Central and Eastern Europe. Formerly with BASF AG and its subsidiaries in the US, Canada, UK and Australia.

No. of shares: 383,750 privately owned (including family) and 4.97% in Maas Biolab, LLC which owns 13.94% of NeuroVive

Non-affiliated to the management, company and major owners.



New election of

Carl Fredrik Olsson (1962)

Businessman

Investments activities through Baulos Capital Belgium SA with focus on LifeScience companies. Apart from the investment in NeuroVive AB Olsson also invested in A1M Pharma AB, Xintela AB, CombiGene AB and Enorama Pharma AB. Olsson also runs the Château Baulos la Vergne winery outside Bordeaux.

No of shares: 15 000 privately owned, 25% of Baulos Capital Belgium SA which owns 3,860,000 shares and 70% of Baulos International SA which owns 20,000 shares.

Affiliated to major owners.